Long-Acting Injectable Antiretroviral Therapy: Coverage and Cost-Sharing Considerations for RWHAP Clients
Resource updated 09/19/2023
Resource updated 09/19/2023
Resource updated 08/21/2023
Resource updated 09/14/2023
Resource updated 10/05/2023
Blog updated 11/15/2022
Resous sa a ofri eksplikasyon sou Medicare pou konsomatè yo pandan y ap konsidere enskripsyon an. Konsomatè yo pral revize diferan pati Medicare (Pati A, B, C, ak D) epi konprann diferans ki genyen ant plan Original Medicare ak Medicare Advantage la.
Resource updated 09/19/2023
Resource updated 09/19/2023
Resource from the RWHAP Best Practices Compilation updated on 01/03/2024
Resource updated 09/14/2023
Resource updated 09/14/2023
Resource updated 10/13/2023
Resource updated 02/12/2024
Resource updated 10/13/2023
Resource updated 02/07/2024
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
Resource from the RWHAP Best Practices Compilation updated on 02/12/2024
Resource from the RWHAP Best Practices Compilation updated on 01/07/2024
In a single-center restrospective cohort study, patients with extensive treatment experience and history of virologic failure and multi-drug resistance underwent simplification of ARV salvage regimens with a median pill burden reduction of six pills per day. This strategy led to high rates of virologic suppression.
Resource (Conference Presentation) updated 09/14/2023